CSIMarket Company Name, Ticker, Industry, else..



Best Performing Stocks In Biotechnology & Pharmaceuticals Industry Today


 1 Day   Week  Current Month of September  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares declined by -1.24% on average, in Biotechnology & Pharmaceuticals Industry today.

Here are the best performing stocks in Biotechnology & Pharmaceuticals Industry.




BIEI

$0.0013

$0.0003 30.00%
Today's


BIEI

$0.0013

$0.0003 30.00%



Premier Biomedical Inc

Premier Biomedical Inc stock went up 30.00% today.


Premier Biomedical Inc operates as a biotechnology company that develops and commercializes medical treatments for various diseases. Their business model focuses on researching, developing, and marketing novel therapies leveraging their proprietary technology and partnerships with healthcare providers and organizations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.215 mill. $ 0.014 mill. $ -0.374 mill. 165 mill. - Y/Y -85.63 %
Market Cap. Revenues TTM Net Income TTM

$ 0.215 mill.
$ 0.014 mill.


$ -0.374 mill.
Employees Shares Outstanding P/E

-
165 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -85.63 %
MRQ Y/Y - %


ALBT

$0.341

$0.0619 22.18%
Today's


ALBT

$0.341

$0.0619 22.18%





shares went up 22.18% today.


Avalon Globocare Corp*s business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.826 mill. $ 1.281 mill. $ -7.528 mill. 11 mill. - Y/Y 10.71 %
Market Cap. Revenues TTM Net Income TTM

$ 3.826 mill.
$ 1.281 mill.


$ -7.528 mill.
Employees Shares Outstanding P/E

-
11 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 10.71 %
MRQ Y/Y - %


TARS

$30.59

$3.2800 12.01%
Today's


TARS

$30.59

$3.2800 12.01%



Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc shares improved 12.01% today.


Tarsus Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics to treat various eye diseases. Their business model involves identifying promising drug candidates, conducting rigorous research and clinical trials, and seeking regulatory approvals for their products. They then partner with larger pharmaceutical companies or directly market and sell their approved therapies to healthcare providers and patients to generate revenue.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,157.013 mill. $ 83.374 mill. $ -150.071 mill. 38 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,157.013 mill.
$ 83.374 mill.


$ -150.071 mill.
Employees Shares Outstanding P/E

-
38 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


VOR

$0.908

$0.0830 10.06%
Today's


VOR

$0.908

$0.0830 10.06%



Vor Biopharma Inc

Vor Biopharma Inc shares increased 10.06% today.


Vor Biopharma Inc*s business model focuses on developing novel cell therapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 61.388 mill. $ - mill. $ -115.512 mill. 68 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 61.388 mill.
$ - mill.


$ -115.512 mill.
Employees Shares Outstanding P/E

-
68 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ZIVO

$11

$1.0000 10.00%
Today's


ZIVO

$11

$1.0000 10.00%



Zivo Bioscience Inc

Zivo Bioscience Inc shares increased 10.00% today.


Zivo Bioscience Inc*s business model is centered around researching, developing, and commercializing naturally derived compounds for various applications in human and animal health. They focus on harnessing the potential of proprietary algal cultures to produce high-value, sustainable bioactive compounds. By leveraging their expertise in algae-based technologies, Zivo Bioscience aims to generate revenue through partnerships, licensing, and commercial agreements in industries such as functional foods, dietary supplements, and pharmaceuticals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 32.578 mill. $ - mill. $ -13.248 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 32.578 mill.
$ - mill.


$ -13.248 mill.
Employees Shares Outstanding P/E

2
3 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


PASG

$0.704

$0.0639 9.98%
Today's


PASG

$0.704

$0.0639 9.98%



Passage Bio Inc

Passage Bio Inc shares increased 9.98% today.


Passage Bio Inc*s business model focuses on developing and commercializing innovative genetic therapies for rare, monogenic central nervous system disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 43.424 mill. $ - mill. $ -76.570 mill. 62 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 43.424 mill.
$ - mill.


$ -76.570 mill.
Employees Shares Outstanding P/E

-
62 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ALEC

$4.85

$0.3300 7.30%
Today's


ALEC

$4.85

$0.3300 7.30%



Alector Inc

Alector Inc shares improved 7.30% today.


Alector Inc*s business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 407.051 mill. $ 96.312 mill. $ -141.385 mill. 84 mill. - Y/Y -38.67 %
Market Cap. Revenues TTM Net Income TTM

$ 407.051 mill.
$ 96.312 mill.


$ -141.385 mill.
Employees Shares Outstanding P/E

155
84 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -38.67 %
MRQ Y/Y - %


EVAX

$3.45

$0.2300 7.14%
Today's


EVAX

$3.45

$0.2300 7.14%



Evaxion Biotech A

Evaxion Biotech A stock improved 7.14% today.


Evaxion Biotech is a company that operates on a business model centered around the development and commercialization of innovative immunotherapies, leveraging artificial intelligence and machine learning technologies to identify and target specific antigens for the treatment of cancer and infectious diseases. These therapies are intended to improve patient outcomes and bring about advancements in the field of precision medicine.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 94.236 mill. $ 0.073 mill. $ -22.125 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 94.236 mill.
$ 0.073 mill.


$ -22.125 mill.
Employees Shares Outstanding P/E

-
27 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ELUT

$4.26

$0.2200 5.45%
Today's


ELUT

$4.26

$0.2200 5.45%



Elutia Inc

Elutia Inc shares improved 5.45% today.


Elutia Inc operates as a technology company that specializes in the design and manufacturing of high-performance air purification systems. Their business model focuses on developing innovative and sustainable solutions to improve indoor air quality for various industries such as healthcare, education, hospitality, and more. By incorporating advanced technology and providing reliable products, Elutia aims to create a healthier and safer environment for their customers while also driving revenue through the sale and maintenance of their air purification systems.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 106.075 mill. $ 24.013 mill. $ -65.235 mill. 25 mill. - Y/Y -41.89 %
Market Cap. Revenues TTM Net Income TTM

$ 106.075 mill.
$ 24.013 mill.


$ -65.235 mill.
Employees Shares Outstanding P/E

-
25 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -41.89 %
MRQ Y/Y - %


PLUR

$5.45

$0.2700 5.21%
Today's


PLUR

$5.45

$0.2700 5.21%



Pluri Inc

Pluri Inc shares went up 5.21% today.


Pluri Inc*s business model revolves around providing digital solutions and services to various clients. They leverage their expertise and technology to offer customized software development, IT consulting, and digital marketing services. With a focus on delivering tailored solutions, Pluri Inc aims to meet the specific needs and goals of their clients and support their growth in the digital landscape.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 28.455 mill. $ 0.341 mill. $ -22.088 mill. 5 mill. - Y/Y -18.39 %
Market Cap. Revenues TTM Net Income TTM

$ 28.455 mill.
$ 0.341 mill.


$ -22.088 mill.
Employees Shares Outstanding P/E

-
5 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -18.39 %
MRQ Y/Y - %


ALGS

$12.51

$0.5700 4.77%
Today's


ALGS

$12.51

$0.5700 4.77%



Aligos Therapeutics Inc

Aligos Therapeutics Inc stock increased 4.77% today.


Aligos Therapeutics Inc*s business model involves developing innovative therapeutics for the treatment of viral diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 544.147 mill. $ 16.385 mill. $ -81.673 mill. 44 mill. - Y/Y -21.12 %
Market Cap. Revenues TTM Net Income TTM

$ 544.147 mill.
$ 16.385 mill.


$ -81.673 mill.
Employees Shares Outstanding P/E

-
44 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -21.12 %
MRQ Y/Y - %


TCBP

$7.85

$0.3500 4.67%
Today's


TCBP

$7.85

$0.3500 4.67%



Tc Biopharm holdings Plc

Tc Biopharm Holdings Plc shares improved 4.67% today.


Tc Biopharm Holdings Plc*s business model revolves around the development and commercialization of innovative cell therapies for the treatment of various diseases and medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 236.588 mill. $ - mill. $ -10.619 mill. 30 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 236.588 mill.
$ - mill.


$ -10.619 mill.
Employees Shares Outstanding P/E

-
30 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ESLA

$1.1

$0.0400 3.77%
Today's


ESLA

$1.1

$0.0400 3.77%





stock improved 3.77% today.


Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 39.071 mill. $ - mill. $ -4.927 mill. 36 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 39.071 mill.
$ - mill.


$ -4.927 mill.
Employees Shares Outstanding P/E

-
36 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


EDIT

$3.59

$0.1000 2.87%
Today's


EDIT

$3.59

$0.1000 2.87%



Editas Medicine Inc

Editas Medicine Inc shares increased 2.87% today.


Editas Medicine Inc.*s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 295.494 mill. $ 67.033 mill. $ -193.450 mill. 82 mill. - Y/Y -82.23 %
Market Cap. Revenues TTM Net Income TTM

$ 295.494 mill.
$ 67.033 mill.


$ -193.450 mill.
Employees Shares Outstanding P/E

-
82 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -82.23 %
MRQ Y/Y - %


NKGN

$0.7827

$0.0186 2.43%
Today's


NKGN

$0.7827

$0.0186 2.43%



Nkgen Biotech Inc

Nkgen Biotech Inc shares increased 2.43% today.


Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17.169 mill. $ -10.087 mill. $ -88.715 mill. 22 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 17.169 mill.
$ -10.087 mill.


$ -88.715 mill.
Employees Shares Outstanding P/E

-
22 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


DTIL

$9.94

$0.2100 2.16%
Today's


DTIL

$9.94

$0.2100 2.16%



Precision Biosciences Inc

Precision Biosciences Inc shares increased 2.16% today.


Precision Biosciences Inc operates under a business model focused on gene editing. They develop and commercialize its ARCUS genome editing platform to create innovative therapies for genetic diseases and cancer. The company offers its gene editing capabilities to partners and collaborates on various research and development projects.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 38.161 mill. $ 52.287 mill. $ -73.518 mill. 4 mill. - Y/Y 78.19 %
Market Cap. Revenues TTM Net Income TTM

$ 38.161 mill.
$ 52.287 mill.


$ -73.518 mill.
Employees Shares Outstanding P/E

-
4 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 78.19 %
MRQ Y/Y - %


IKNA

$1.69

$0.0300 1.81%
Today's


IKNA

$1.69

$0.0300 1.81%



Ikena Oncology Inc

Ikena Oncology Inc stock improved 1.81% today.


Ikena Oncology Inc*s business model focuses on developing innovative cancer therapies through targeted drug discovery and development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 73.410 mill. $ 13.952 mill. $ -62.774 mill. 43 mill. - Y/Y -81.49 %
Market Cap. Revenues TTM Net Income TTM

$ 73.410 mill.
$ 13.952 mill.


$ -62.774 mill.
Employees Shares Outstanding P/E

-
43 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -81.49 %
MRQ Y/Y - %


OTLK

$7.95

$0.1300 1.66%
Today's


OTLK

$7.95

$0.1300 1.66%



Outlook Therapeutics Inc

Outlook Therapeutics Inc shares went up 1.66% today.


Outlook Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing monoclonal antibody-based therapies for various ophthalmic indications. Their business model revolves around leveraging their expertise in developing cost-effective, innovative treatments that address unmet medical needs in the ophthalmic market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 202.538 mill. $ - mill. $ -94.049 mill. 25 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 202.538 mill.
$ - mill.


$ -94.049 mill.
Employees Shares Outstanding P/E

-
25 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


KRBP

$2.03

$0.0300 1.50%
Today's


KRBP

$2.03

$0.0300 1.50%



Kiromic Biopharma Inc

Kiromic Biopharma Inc stock increased 1.50% today.


Kiromic Biopharma Inc is a biotechnology company that focuses on developing targeted immunotherapies for the treatment of cancer. Their business model revolves around utilizing their proprietary technology platforms to identify tumor-specific antigens and develop personalized therapies to effectively target and eliminate cancer cells.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.047 mill. $ - mill. $ -21.858 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.047 mill.
$ - mill.


$ -21.858 mill.
Employees Shares Outstanding P/E

-
0 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


VIR

$7.76

$0.1100 1.44%
Today's


VIR

$7.76

$0.1100 1.44%



Vir Biotechnology Inc

Vir Biotechnology Inc shares went up 1.44% today.


Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,057.174 mill. $ 78.877 mill. $ -483.040 mill. 136 mill. - Y/Y -19.02 %
Market Cap. Revenues TTM Net Income TTM

$ 1,057.174 mill.
$ 78.877 mill.


$ -483.040 mill.
Employees Shares Outstanding P/E

-
136 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -19.02 %
MRQ Y/Y - %


IPSC

$1.46

$0.0200 1.39%
Today's


IPSC

$1.46

$0.0200 1.39%



Century Therapeutics inc

Century Therapeutics Inc stock improved 1.39% today.


Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 119.855 mill. $ 2.042 mill. $ -131.387 mill. 82 mill. - Y/Y 678.79 %
Market Cap. Revenues TTM Net Income TTM

$ 119.855 mill.
$ 2.042 mill.


$ -131.387 mill.
Employees Shares Outstanding P/E

-
82 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 678.79 %
MRQ Y/Y - %


SCNI

$3.5984

$0.0472 1.33%
Today's


SCNI

$3.5984

$0.0472 1.33%



Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd stock went up 1.33% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,622.959 mill. $ - mill. $ 6.500 mill. 1,563 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,622.959 mill.
$ - mill.


$ 6.500 mill.
Employees Shares Outstanding P/E

-
1,563 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y 0.00 %


CLDI

$1.155

$0.0150 1.32%
Today's


CLDI

$1.155

$0.0150 1.32%



Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc stock improved 1.32% today.


Calidi Biotherapeutics Inc*s business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 41.063 mill. $ - mill. $ -34.216 mill. 36 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 41.063 mill.
$ - mill.


$ -34.216 mill.
Employees Shares Outstanding P/E

-
36 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


RGEN

$147.07

$1.9000 1.31%
Today's


RGEN

$147.07

$1.9000 1.31%



Repligen Corp

Repligen Corp stock went up 1.31% today.


Repligen Corp operates as a bioprocessing company that provides products and services to the life sciences industry. They focus on the development, production, and distribution of highly specialized consumable products used in the manufacture of biological drugs. Repligen*s business model revolves around helping their customers enhance productivity, improve quality, and reduce production costs in the biopharmaceutical manufacturing process.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 8,351.738 mill. $ 669.783 mill. $ 115.794 mill. 57 mill. 72.10 Y/Y -29.66 %
Market Cap. Revenues TTM Net Income TTM

$ 8,351.738 mill.
$ 669.783 mill.


$ 115.794 mill.
Employees Shares Outstanding P/E

1,170
57 mill.
72.10
Revenue Growth Income Growth

MRQ Y/Y -29.66 %
MRQ Y/Y -55.03 %


ACHL

$0.7199

$0.0091 1.28%
Today's


ACHL

$0.7199

$0.0091 1.28%



Achilles Therapeutics Plc

Achilles Therapeutics Plc shares increased 1.28% today.


Achilles Therapeutics Plc has a business model focused on developing personalized cancer immunotherapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 28.177 mill. $ - mill. $ -71.176 mill. 39 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 28.177 mill.
$ - mill.


$ -71.176 mill.
Employees Shares Outstanding P/E

-
39 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ACLX

$71.25

$0.8800 1.25%
Today's


ACLX

$71.25

$0.8800 1.25%



Arcellx Inc

Arcellx Inc shares increased 1.25% today.


Arcellx Inc operates on a business model focused on developing and commercializing next-generation cell therapies for the treatment of various diseases by utilizing its proprietary ARC-SparX platform technology. The company intends to leverage its technology to create novel and improved therapies, targeting both liquid and solid tumors, aiming for better patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,451.214 mill. $ 47.171 mill. $ -129.526 mill. 48 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3,451.214 mill.
$ 47.171 mill.


$ -129.526 mill.
Employees Shares Outstanding P/E

-
48 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


IMVT

$34.03

$0.4100 1.22%
Today's


IMVT

$34.03

$0.4100 1.22%



Immunovant Inc

Immunovant Inc shares improved 1.22% today.


Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4,971.297 mill. $ - mill. $ -272.549 mill. 146 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4,971.297 mill.
$ - mill.


$ -272.549 mill.
Employees Shares Outstanding P/E

-
146 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


PSTX

$2.74

$0.0300 1.11%
Today's


PSTX

$2.74

$0.0300 1.11%



Poseida Therapeutics Inc

Poseida Therapeutics Inc stock improved 1.11% today.


Poseida Therapeutics Inc*s business model revolves around developing and commercializing gene therapies for a wide range of diseases and conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 251.801 mill. $ 52.459 mill. $ -132.011 mill. 92 mill. - Y/Y -91.96 %
Market Cap. Revenues TTM Net Income TTM

$ 251.801 mill.
$ 52.459 mill.


$ -132.011 mill.
Employees Shares Outstanding P/E

-
92 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -91.96 %
MRQ Y/Y - %


RGNX

$11.48

$0.1000 0.88%
Today's


RGNX

$11.48

$0.1000 0.88%



Regenxbio Inc

Regenxbio Inc stock increased 0.88% today.


Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 503.720 mill. $ 99.374 mill. $ -260.540 mill. 44 mill. - Y/Y 9.06 %
Market Cap. Revenues TTM Net Income TTM

$ 503.720 mill.
$ 99.374 mill.


$ -260.540 mill.
Employees Shares Outstanding P/E

300
44 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 9.06 %
MRQ Y/Y - %


XTNT

$0.5651

$0.0046 0.82%
Today's


XTNT

$0.5651

$0.0046 0.82%



Xtant Medical Holdings Inc

Xtant Medical Holdings Inc stock increased 0.82% today.


Xtant Medical Holdings Inc operates as a medical technology company that focuses on the development, production, and distribution of regenerative medical products and devices. It primarily offers orthopedic and spinal surgical implants and instruments, providing solutions to surgeons and patients for enhancing healing and improving patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 73.577 mill. $ 99.826 mill. $ -1.662 mill. 130 mill. - Y/Y 52.16 %
Market Cap. Revenues TTM Net Income TTM

$ 73.577 mill.
$ 99.826 mill.


$ -1.662 mill.
Employees Shares Outstanding P/E

-
130 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 52.16 %
MRQ Y/Y - %


TIL

$14.25

$0.1000 0.71%
Today's


TIL

$14.25

$0.1000 0.71%



Instil Bio Inc

Instil Bio Inc stock increased 0.71% today.


Instil Bio Inc operates with a business model focusing on developing and commercializing innovative cell therapy products for the treatment of cancer. They aim to leverage advanced technologies and strategic partnerships to advance their pipeline and bring novel therapies to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 92.681 mill. $ - mill. $ -125.313 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 92.681 mill.
$ - mill.


$ -125.313 mill.
Employees Shares Outstanding P/E

-
7 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ALVR

$0.7642

$0.0042 0.55%
Today's


ALVR

$0.7642

$0.0042 0.55%



Allovir Inc

Allovir Inc stock increased 0.55% today.


Allovir Inc*s business model is centered around the development and commercialization of innovative cell therapies for patients with life-threatening viral diseases. They focus on utilizing advanced technologies to engineer allogeneic, off-the-shelf, and ready-to-use T cell therapies. By partnering with research institutions and leveraging strategic collaborations, Allovir aims to bring novel treatments to market and address unmet medical needs in the field of viral diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 87.038 mill. $ - mill. $ -168.858 mill. 114 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 87.038 mill.
$ - mill.


$ -168.858 mill.
Employees Shares Outstanding P/E

-
114 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


CGEN

$1.83

$0.0100 0.55%
Today's


CGEN

$1.83

$0.0100 0.55%



Compugen Ltd

Compugen Ltd stock went up 0.55% today.


Compugen Ltd is a technology company that operates on a business model focused on providing innovative solutions to its clients. They utilize their expertise in fields like artificial intelligence, data analytics, and cloud technology to develop software and hardware solutions tailored to meet specific customer requirements. Their business model revolves around offering comprehensive IT services and products aimed at enhancing organizational efficiency and productivity.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 158.397 mill. $ 7.500 mill. $ -33.694 mill. 87 mill. - Y/Y 25.00 %
Market Cap. Revenues TTM Net Income TTM

$ 158.397 mill.
$ 7.500 mill.


$ -33.694 mill.
Employees Shares Outstanding P/E

-
87 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 25.00 %
MRQ Y/Y - %


VXRT

$0.8852

$0.0046 0.52%
Today's


VXRT

$0.8852

$0.0046 0.52%



Vaxart Inc

Vaxart Inc stock went up 0.52% today.


Vaxart Inc*s business model involves the development of oral vaccines through their proprietary tablet vaccine delivery platform.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 163.499 mill. $ 13.928 mill. $ -75.658 mill. 185 mill. - Y/Y 371.35 %
Market Cap. Revenues TTM Net Income TTM

$ 163.499 mill.
$ 13.928 mill.


$ -75.658 mill.
Employees Shares Outstanding P/E

-
185 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 371.35 %
MRQ Y/Y - %


TECX

$18.36

$0.0900 0.49%
Today's


TECX

$18.36

$0.0900 0.49%



Tectonic Therapeutic Inc

Tectonic Therapeutic Inc shares went up 0.49% today.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 53.609 mill. $ - mill. $ 8.271 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 53.609 mill.
$ - mill.


$ 8.271 mill.
Employees Shares Outstanding P/E

-
3 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


EXAI

$4.9

$0.0200 0.41%
Today's


EXAI

$4.9

$0.0200 0.41%



Exscientia Plc

Exscientia Plc shares went up 0.41% today.


Exscientia Plc is a leading artificial intelligence (AI) drug discovery company that utilizes cutting-edge technologies in the pharmaceutical industry. Their business model focuses on applying AI algorithms to design and optimize small molecules for drug development, streamlining the drug discovery process and reducing associated costs. By combining AI-powered drug design with high-throughput screening, Exscientia aims to accelerate the discovery of novel, effective therapies for various diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 244.393 mill. $ - mill. $ 0.000 mill. 50 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 244.393 mill.
$ - mill.


$ 0.000 mill.
Employees Shares Outstanding P/E

-
50 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ACAB

$11.22

$0.0400 0.36%
Today's


ACAB

$11.22

$0.0400 0.36%



Atlantic Coastal Acquisition Corp Ii

Atlantic Coastal Acquisition Corp Ii shares increased 0.36% today.


Atlantic Coastal Acquisition Corp II is a blank check company that intends to focus on acquiring, engaging in a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the consumer sector. Their goal is to create long-term value for their shareholders through strategic acquisitions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 7.488 mill. $ - mill. $ -1.439 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 7.488 mill.
$ - mill.


$ -1.439 mill.
Employees Shares Outstanding P/E

-
1 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


GENT

$10.43

$0.0300 0.29%
Today's


GENT

$10.43

$0.0300 0.29%



Gentium S.p.a.

Gentium S.p.a. stock went up 0.29% today.


Gentium S.p.a. operates on a business model centered around the development and commercialization of pharmaceutical products. They focus on the research, production, and distribution of innovative therapies for various medical conditions. By leveraging their expertise in the pharmaceutical industry, they aim to provide effective treatments and improve the overall healthcare landscape.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 173.167 mill. $ 53.151 mill. $ 26.452 mill. 17 mill. 6.52 Y/Y 47.79 %
Market Cap. Revenues TTM Net Income TTM

$ 173.167 mill.
$ 53.151 mill.


$ 26.452 mill.
Employees Shares Outstanding P/E

-
17 mill.
6.52
Revenue Growth Income Growth

MRQ Y/Y 47.79 %
MRQ Y/Y -13.15 %


CGEM

$17.98

$0.0500 0.28%
Today's


CGEM

$17.98

$0.0500 0.28%



Cullinan Oncology Inc

Cullinan Oncology Inc stock increased 0.28% today.


Cullinan Oncology Inc*s business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 768.357 mill. $ - mill. $ -156.626 mill. 43 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 768.357 mill.
$ - mill.


$ -156.626 mill.
Employees Shares Outstanding P/E

2
43 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


COEP

$0.1855

$0.0005 0.27%
Today's


COEP

$0.1855

$0.0005 0.27%



Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings Inc stock increased 0.27% today.


Coeptis Therapeutics Holdings Inc. is a pharmaceutical company that focuses on the development and commercialization of innovative therapies. Their business model involves researching, formulating, and manufacturing drugs to address unmet medical needs in various therapeutic areas. They aim to bring these treatments to market to improve patient outcomes and generate revenue through sales and licensing agreements.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.969 mill. $ - mill. $ -16.143 mill. 38 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.969 mill.
$ - mill.


$ -16.143 mill.
Employees Shares Outstanding P/E

-
38 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %



 1 Day   Week  Current Month of September  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com